Regeneron PharmaceuticalsSTU:RGO +1.76%85 FCF Margin % is 22.17% as of Mar. 2026, which is 18% below its 10-year median of 27.08. GuruFocus rates STU:RGO with a GF Score™ of 85/100 and a GF Value™ of €788.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 91.45% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RGO vs ALNY, RVMD, ONC: FCF Margin % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (STU:RGO) has a FCF Margin % of 22.17% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Regeneron Pharmaceuticals and its competitors. This is 18% below median its historical median of 27.08. Over the past decade, Regeneron Pharmaceuticals' FCF Margin % has ranged from 17.62 to 40.63. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #82 out of 959 companies in the Biotechnology industry, placing it in the top 8.6%.
Is Regeneron Pharmaceuticals' FCF Margin % too high?
Regeneron Pharmaceuticals' current FCF Margin % of 22.17% is 18% below median its 10-year median of 27.08. Over the past 10 years, this metric has ranged from a low of 17.62 to a high of 40.63. Based on the distribution chart, Regeneron Pharmaceuticals ranks #82 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' FCF Margin % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #82 out of 959 companies for FCF Margin %. This places Regeneron Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. Historically, Regeneron Pharmaceuticals' own FCF Margin % has ranged from 17.62 to 40.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current FCF Margin % is 22.17%, which is 18% below median its own 10-year median of 27.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €788.02, compared to a current price of €554.60 — trading 29.6% below its estimated fair value. The current FCF Margin % is 22.17%, which is 18% below median its 10-year median of 27.08. Regeneron Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current FCF Margin % is 22.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €554.60 is trading 29.6% below its estimated GF Value™ of €788.02.
GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for STU:RGO:
FCF Margin %: 22.17% (18% below median its 10-year median of 27.08)
GF Value™: €788.02 vs. price of €554.60 (29.6% below fair value)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
85GF Score
Get the complete analysis for STU:RGO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
